|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: OSBP2 |
Gene summary for OSBP2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | OSBP2 | Gene ID | 23762 |
| Gene name | oxysterol binding protein 2 | |
| Gene Alias | HLM | |
| Cytomap | 22q12.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q969R2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 23762 | OSBP2 | CCI_1 | Human | Cervix | CC | 1.49e-06 | 3.45e-01 | 0.528 |
| 23762 | OSBP2 | CCI_3 | Human | Cervix | CC | 1.51e-04 | 2.18e-01 | 0.516 |
| 23762 | OSBP2 | CCII_1 | Human | Cervix | CC | 1.30e-02 | 1.40e-01 | 0.3249 |
| 23762 | OSBP2 | sample1 | Human | Cervix | CC | 2.80e-20 | 5.15e-01 | 0.0959 |
| 23762 | OSBP2 | T1 | Human | Cervix | CC | 2.04e-34 | 6.07e-01 | 0.0918 |
| 23762 | OSBP2 | AEH-subject5 | Human | Endometrium | AEH | 3.36e-02 | 1.41e-01 | -0.2953 |
| 23762 | OSBP2 | EEC-subject1 | Human | Endometrium | EEC | 1.82e-06 | 2.25e-01 | -0.2682 |
| 23762 | OSBP2 | EEC-subject5 | Human | Endometrium | EEC | 8.79e-03 | 1.52e-01 | -0.249 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| OSBP2 | SNV | Missense_Mutation | rs367777319 | c.2242N>A | p.Gly748Ser | p.G748S | Q969R2 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AR-A1AY-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Doxorubicin | SD |
| OSBP2 | SNV | Missense_Mutation | c.2695G>A | p.Gly899Ser | p.G899S | Q969R2 | protein_coding | tolerated(0.06) | possibly_damaging(0.883) | TCGA-B6-A0X1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| OSBP2 | deletion | Frame_Shift_Del | novel | c.443delA | p.Lys148SerfsTer49 | p.K148Sfs*49 | Q969R2 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| OSBP2 | SNV | Missense_Mutation | novel | c.2109N>T | p.Glu703Asp | p.E703D | Q969R2 | protein_coding | tolerated(0.47) | benign(0.048) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| OSBP2 | SNV | Missense_Mutation | rs746490863 | c.1433N>A | p.Gly478Asp | p.G478D | Q969R2 | protein_coding | deleterious(0.04) | benign(0.071) | TCGA-C5-A3HF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| OSBP2 | SNV | Missense_Mutation | c.1145G>T | p.Ser382Ile | p.S382I | Q969R2 | protein_coding | deleterious(0.04) | probably_damaging(0.947) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| OSBP2 | SNV | Missense_Mutation | rs773995691 | c.1066N>T | p.Arg356Trp | p.R356W | Q969R2 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AA-3949-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| OSBP2 | SNV | Missense_Mutation | rs753497112 | c.835N>A | p.Val279Met | p.V279M | Q969R2 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AA-A02R-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| OSBP2 | SNV | Missense_Mutation | c.1264N>A | p.Gly422Ser | p.G422S | Q969R2 | protein_coding | tolerated(0.49) | benign(0.041) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| OSBP2 | SNV | Missense_Mutation | novel | c.1306N>A | p.Leu436Ile | p.L436I | Q969R2 | protein_coding | tolerated(0.24) | benign(0.007) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |